GSK plc

GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLAXF stands at 75.97B. In comparison, LLY has a market cap of 736.48B. Regarding current trading prices, GLAXF is priced at $18.75, while LLY trades at $776.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLAXF currently has a P/E ratio of 18.56, whereas LLY's P/E ratio is 63.32. In terms of profitability, GLAXF's ROE is +0.22%, compared to LLY's ROE of +0.77%. Regarding short-term risk, GLAXF is less volatile compared to LLY. This indicates potentially lower risk in terms of short-term price fluctuations for GLAXF.

GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLAXF stands at 75.97B. In comparison, AZN has a market cap of 434.49B. Regarding current trading prices, GLAXF is priced at $18.75, while AZN trades at $70.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLAXF currently has a P/E ratio of 18.56, whereas AZN's P/E ratio is 28.25. In terms of profitability, GLAXF's ROE is +0.22%, compared to AZN's ROE of +0.19%. Regarding short-term risk, GLAXF is more volatile compared to AZN. This indicates potentially higher risk in terms of short-term price fluctuations for GLAXF.

GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLAXF stands at 75.97B. In comparison, JNJ has a market cap of 378.95B. Regarding current trading prices, GLAXF is priced at $18.75, while JNJ trades at $157.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLAXF currently has a P/E ratio of 18.56, whereas JNJ's P/E ratio is 17.49. In terms of profitability, GLAXF's ROE is +0.22%, compared to JNJ's ROE of +0.30%. Regarding short-term risk, GLAXF is less volatile compared to JNJ. This indicates potentially lower risk in terms of short-term price fluctuations for GLAXF.

GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLAXF stands at 75.97B. In comparison, ABBV has a market cap of 332.39B. Regarding current trading prices, GLAXF is priced at $18.75, while ABBV trades at $187.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLAXF currently has a P/E ratio of 18.56, whereas ABBV's P/E ratio is 80.30. In terms of profitability, GLAXF's ROE is +0.22%, compared to ABBV's ROE of +0.70%. Regarding short-term risk, GLAXF is less volatile compared to ABBV. This indicates potentially lower risk in terms of short-term price fluctuations for GLAXF.

GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLAXF stands at 75.97B. In comparison, NVO has a market cap of 302.29B. Regarding current trading prices, GLAXF is priced at $18.75, while NVO trades at $67.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLAXF currently has a P/E ratio of 18.56, whereas NVO's P/E ratio is 19.69. In terms of profitability, GLAXF's ROE is +0.22%, compared to NVO's ROE of +0.85%. Regarding short-term risk, GLAXF is less volatile compared to NVO. This indicates potentially lower risk in terms of short-term price fluctuations for GLAXF.

GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLAXF stands at 75.97B. In comparison, RHHBF has a market cap of 260.53B. Regarding current trading prices, GLAXF is priced at $18.75, while RHHBF trades at $345.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLAXF currently has a P/E ratio of 18.56, whereas RHHBF's P/E ratio is 27.70. In terms of profitability, GLAXF's ROE is +0.22%, compared to RHHBF's ROE of +0.35%. Regarding short-term risk, GLAXF is more volatile compared to RHHBF. This indicates potentially higher risk in terms of short-term price fluctuations for GLAXF.

GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLAXF stands at 75.97B. In comparison, RHHBY has a market cap of 258.93B. Regarding current trading prices, GLAXF is priced at $18.75, while RHHBY trades at $40.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLAXF currently has a P/E ratio of 18.56, whereas RHHBY's P/E ratio is 25.85. In terms of profitability, GLAXF's ROE is +0.22%, compared to RHHBY's ROE of +0.35%. Regarding short-term risk, GLAXF is more volatile compared to RHHBY. This indicates potentially higher risk in terms of short-term price fluctuations for GLAXF.

GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLAXF stands at 75.97B. In comparison, RHHVF has a market cap of 258.38B. Regarding current trading prices, GLAXF is priced at $18.75, while RHHVF trades at $319.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLAXF currently has a P/E ratio of 18.56, whereas RHHVF's P/E ratio is 25.64. In terms of profitability, GLAXF's ROE is +0.22%, compared to RHHVF's ROE of +0.35%. Regarding short-term risk, GLAXF is less volatile compared to RHHVF. This indicates potentially lower risk in terms of short-term price fluctuations for GLAXF.

GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLAXF stands at 75.97B. In comparison, NVS has a market cap of 220.58B. Regarding current trading prices, GLAXF is priced at $18.75, while NVS trades at $111.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLAXF currently has a P/E ratio of 18.56, whereas NVS's P/E ratio is 17.50. In terms of profitability, GLAXF's ROE is +0.22%, compared to NVS's ROE of +0.31%. Regarding short-term risk, GLAXF is more volatile compared to NVS. This indicates potentially higher risk in terms of short-term price fluctuations for GLAXF.

GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLAXF stands at 75.97B. In comparison, AZNCF has a market cap of 215.01B. Regarding current trading prices, GLAXF is priced at $18.75, while AZNCF trades at $138.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLAXF currently has a P/E ratio of 18.56, whereas AZNCF's P/E ratio is 27.90. In terms of profitability, GLAXF's ROE is +0.22%, compared to AZNCF's ROE of +0.19%. Regarding short-term risk, GLAXF is more volatile compared to AZNCF. This indicates potentially higher risk in terms of short-term price fluctuations for GLAXF.

GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLAXF stands at 75.97B. In comparison, NVSEF has a market cap of 208.74B. Regarding current trading prices, GLAXF is priced at $18.75, while NVSEF trades at $110.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLAXF currently has a P/E ratio of 18.56, whereas NVSEF's P/E ratio is 17.24. In terms of profitability, GLAXF's ROE is +0.22%, compared to NVSEF's ROE of +0.31%. Regarding short-term risk, GLAXF is less volatile compared to NVSEF. This indicates potentially lower risk in terms of short-term price fluctuations for GLAXF.

GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLAXF stands at 75.97B. In comparison, MRK has a market cap of 198.97B. Regarding current trading prices, GLAXF is priced at $18.75, while MRK trades at $79.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLAXF currently has a P/E ratio of 18.56, whereas MRK's P/E ratio is 11.49. In terms of profitability, GLAXF's ROE is +0.22%, compared to MRK's ROE of +0.38%. Regarding short-term risk, GLAXF is less volatile compared to MRK. This indicates potentially lower risk in terms of short-term price fluctuations for GLAXF.

GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLAXF stands at 75.97B. In comparison, AMGN has a market cap of 148.31B. Regarding current trading prices, GLAXF is priced at $18.75, while AMGN trades at $275.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLAXF currently has a P/E ratio of 18.56, whereas AMGN's P/E ratio is 25.14. In terms of profitability, GLAXF's ROE is +0.22%, compared to AMGN's ROE of +0.93%. Regarding short-term risk, GLAXF is less volatile compared to AMGN. This indicates potentially lower risk in terms of short-term price fluctuations for GLAXF.

GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLAXF stands at 75.97B. In comparison, SNY has a market cap of 129.33B. Regarding current trading prices, GLAXF is priced at $18.75, while SNY trades at $52.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLAXF currently has a P/E ratio of 18.56, whereas SNY's P/E ratio is 18.54. In terms of profitability, GLAXF's ROE is +0.22%, compared to SNY's ROE of +0.08%. Regarding short-term risk, GLAXF is less volatile compared to SNY. This indicates potentially lower risk in terms of short-term price fluctuations for GLAXF.

GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLAXF stands at 75.97B. In comparison, PFE has a market cap of 129.22B. Regarding current trading prices, GLAXF is priced at $18.75, while PFE trades at $22.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLAXF currently has a P/E ratio of 18.56, whereas PFE's P/E ratio is 16.51. In terms of profitability, GLAXF's ROE is +0.22%, compared to PFE's ROE of +0.09%. Regarding short-term risk, GLAXF is less volatile compared to PFE. This indicates potentially lower risk in terms of short-term price fluctuations for GLAXF.

GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLAXF stands at 75.97B. In comparison, SNYNF has a market cap of 125.95B. Regarding current trading prices, GLAXF is priced at $18.75, while SNYNF trades at $103.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLAXF currently has a P/E ratio of 18.56, whereas SNYNF's P/E ratio is 18.36. In terms of profitability, GLAXF's ROE is +0.22%, compared to SNYNF's ROE of +0.10%. Regarding short-term risk, GLAXF is more volatile compared to SNYNF. This indicates potentially higher risk in terms of short-term price fluctuations for GLAXF.

GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLAXF stands at 75.97B. In comparison, GILD has a market cap of 123.28B. Regarding current trading prices, GLAXF is priced at $18.75, while GILD trades at $98.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLAXF currently has a P/E ratio of 18.56, whereas GILD's P/E ratio is 12.78. In terms of profitability, GLAXF's ROE is +0.22%, compared to GILD's ROE of +0.32%. Regarding short-term risk, GLAXF is less volatile compared to GILD. This indicates potentially lower risk in terms of short-term price fluctuations for GLAXF.

GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLAXF stands at 75.97B. In comparison, BMYMP has a market cap of 102.91B. Regarding current trading prices, GLAXF is priced at $18.75, while BMYMP trades at $831.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLAXF currently has a P/E ratio of 18.56, whereas BMYMP's P/E ratio is 3695.82. In terms of profitability, GLAXF's ROE is +0.22%, compared to BMYMP's ROE of +0.32%. Regarding short-term risk, GLAXF is less volatile compared to BMYMP. This indicates potentially lower risk in terms of short-term price fluctuations for GLAXF.

GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLAXF stands at 75.97B. In comparison, CHGCY has a market cap of 96.96B. Regarding current trading prices, GLAXF is priced at $18.75, while CHGCY trades at $29.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLAXF currently has a P/E ratio of 18.56, whereas CHGCY's P/E ratio is 34.26. In terms of profitability, GLAXF's ROE is +0.22%, compared to CHGCY's ROE of +0.17%. Regarding short-term risk, GLAXF is less volatile compared to CHGCY. This indicates potentially lower risk in terms of short-term price fluctuations for GLAXF.

GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLAXF stands at 75.97B. In comparison, BMY has a market cap of 96.89B. Regarding current trading prices, GLAXF is priced at $18.75, while BMY trades at $47.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLAXF currently has a P/E ratio of 18.56, whereas BMY's P/E ratio is 17.76. In terms of profitability, GLAXF's ROE is +0.22%, compared to BMY's ROE of +0.32%. Regarding short-term risk, GLAXF is less volatile compared to BMY. This indicates potentially lower risk in terms of short-term price fluctuations for GLAXF.

GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLAXF stands at 75.97B. In comparison, CHGCF has a market cap of 93.21B. Regarding current trading prices, GLAXF is priced at $18.75, while CHGCF trades at $56.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLAXF currently has a P/E ratio of 18.56, whereas CHGCF's P/E ratio is 32.55. In terms of profitability, GLAXF's ROE is +0.22%, compared to CHGCF's ROE of +0.17%. Regarding short-term risk, GLAXF is less volatile compared to CHGCF. This indicates potentially lower risk in terms of short-term price fluctuations for GLAXF.

GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLAXF stands at 75.97B. In comparison, CELG-RI has a market cap of 84.90B. Regarding current trading prices, GLAXF is priced at $18.75, while CELG-RI trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLAXF currently has a P/E ratio of 18.56, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, GLAXF's ROE is +0.22%, compared to CELG-RI's ROE of +0.32%. Regarding short-term risk, GLAXF is more volatile compared to CELG-RI. This indicates potentially higher risk in terms of short-term price fluctuations for GLAXF.

GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLAXF stands at 75.97B. In comparison, GSK has a market cap of 75.55B. Regarding current trading prices, GLAXF is priced at $18.75, while GSK trades at $37.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLAXF currently has a P/E ratio of 18.56, whereas GSK's P/E ratio is 18.31. In terms of profitability, GLAXF's ROE is +0.22%, compared to GSK's ROE of +0.22%. Regarding short-term risk, GLAXF is more volatile compared to GSK. This indicates potentially higher risk in terms of short-term price fluctuations for GLAXF.

GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLAXF stands at 75.97B. In comparison, DSNKY has a market cap of 46.80B. Regarding current trading prices, GLAXF is priced at $18.75, while DSNKY trades at $25.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLAXF currently has a P/E ratio of 18.56, whereas DSNKY's P/E ratio is 23.19. In terms of profitability, GLAXF's ROE is +0.22%, compared to DSNKY's ROE of +0.15%. Regarding short-term risk, GLAXF is more volatile compared to DSNKY. This indicates potentially higher risk in terms of short-term price fluctuations for GLAXF.

GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLAXF stands at 75.97B. In comparison, DSKYF has a market cap of 46.67B. Regarding current trading prices, GLAXF is priced at $18.75, while DSKYF trades at $25.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLAXF currently has a P/E ratio of 18.56, whereas DSKYF's P/E ratio is 23.15. In terms of profitability, GLAXF's ROE is +0.22%, compared to DSKYF's ROE of +0.11%. Regarding short-term risk, GLAXF is less volatile compared to DSKYF. This indicates potentially lower risk in terms of short-term price fluctuations for GLAXF.

GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLAXF stands at 75.97B. In comparison, OTSKY has a market cap of 27.21B. Regarding current trading prices, GLAXF is priced at $18.75, while OTSKY trades at $25.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLAXF currently has a P/E ratio of 18.56, whereas OTSKY's P/E ratio is 11.32. In terms of profitability, GLAXF's ROE is +0.22%, compared to OTSKY's ROE of +0.03%. Regarding short-term risk, GLAXF is less volatile compared to OTSKY. This indicates potentially lower risk in terms of short-term price fluctuations for GLAXF.

GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLAXF stands at 75.97B. In comparison, HZNP has a market cap of 26.60B. Regarding current trading prices, GLAXF is priced at $18.75, while HZNP trades at $116.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLAXF currently has a P/E ratio of 18.56, whereas HZNP's P/E ratio is 61.86. In terms of profitability, GLAXF's ROE is +0.22%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, GLAXF is more volatile compared to HZNP. This indicates potentially higher risk in terms of short-term price fluctuations for GLAXF.

GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLAXF stands at 75.97B. In comparison, BAYRY has a market cap of 26.09B. Regarding current trading prices, GLAXF is priced at $18.75, while BAYRY trades at $6.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLAXF currently has a P/E ratio of 18.56, whereas BAYRY's P/E ratio is -8.97. In terms of profitability, GLAXF's ROE is +0.22%, compared to BAYRY's ROE of -0.08%. Regarding short-term risk, GLAXF is less volatile compared to BAYRY. This indicates potentially lower risk in terms of short-term price fluctuations for GLAXF.

GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLAXF stands at 75.97B. In comparison, OTSKF has a market cap of 25.31B. Regarding current trading prices, GLAXF is priced at $18.75, while OTSKF trades at $47.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLAXF currently has a P/E ratio of 18.56, whereas OTSKF's P/E ratio is 10.53. In terms of profitability, GLAXF's ROE is +0.22%, compared to OTSKF's ROE of +0.03%. Regarding short-term risk, GLAXF is more volatile compared to OTSKF. This indicates potentially higher risk in terms of short-term price fluctuations for GLAXF.

GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLAXF stands at 75.97B. In comparison, ALPMF has a market cap of 18.69B. Regarding current trading prices, GLAXF is priced at $18.75, while ALPMF trades at $10.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLAXF currently has a P/E ratio of 18.56, whereas ALPMF's P/E ratio is 52.20. In terms of profitability, GLAXF's ROE is +0.22%, compared to ALPMF's ROE of +0.01%. Regarding short-term risk, GLAXF is more volatile compared to ALPMF. This indicates potentially higher risk in terms of short-term price fluctuations for GLAXF.

GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLAXF stands at 75.97B. In comparison, ORINY has a market cap of 18.06B. Regarding current trading prices, GLAXF is priced at $18.75, while ORINY trades at $32.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLAXF currently has a P/E ratio of 18.56, whereas ORINY's P/E ratio is 23.18. In terms of profitability, GLAXF's ROE is +0.22%, compared to ORINY's ROE of +0.37%. Regarding short-term risk, GLAXF is more volatile compared to ORINY. This indicates potentially higher risk in terms of short-term price fluctuations for GLAXF.

GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLAXF stands at 75.97B. In comparison, ALPMY has a market cap of 17.75B. Regarding current trading prices, GLAXF is priced at $18.75, while ALPMY trades at $9.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLAXF currently has a P/E ratio of 18.56, whereas ALPMY's P/E ratio is 52.18. In terms of profitability, GLAXF's ROE is +0.22%, compared to ALPMY's ROE of +0.01%. Regarding short-term risk, GLAXF is less volatile compared to ALPMY. This indicates potentially lower risk in terms of short-term price fluctuations for GLAXF.

GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLAXF stands at 75.97B. In comparison, BIIB has a market cap of 17.17B. Regarding current trading prices, GLAXF is priced at $18.75, while BIIB trades at $117.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLAXF currently has a P/E ratio of 18.56, whereas BIIB's P/E ratio is 11.58. In terms of profitability, GLAXF's ROE is +0.22%, compared to BIIB's ROE of +0.09%. Regarding short-term risk, GLAXF is less volatile compared to BIIB. This indicates potentially lower risk in terms of short-term price fluctuations for GLAXF.

GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLAXF stands at 75.97B. In comparison, GIKLY has a market cap of 11.93B. Regarding current trading prices, GLAXF is priced at $18.75, while GIKLY trades at $4.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLAXF currently has a P/E ratio of 18.56, whereas GIKLY's P/E ratio is 36.92. In terms of profitability, GLAXF's ROE is +0.22%, compared to GIKLY's ROE of +0.03%. Regarding short-term risk, GLAXF is less volatile compared to GIKLY. This indicates potentially lower risk in terms of short-term price fluctuations for GLAXF.

GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLAXF stands at 75.97B. In comparison, RCDTF has a market cap of 11.56B. Regarding current trading prices, GLAXF is priced at $18.75, while RCDTF trades at $56.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLAXF currently has a P/E ratio of 18.56, whereas RCDTF's P/E ratio is 24.80. In terms of profitability, GLAXF's ROE is +0.22%, compared to RCDTF's ROE of +0.23%. Regarding short-term risk, GLAXF is less volatile compared to RCDTF. This indicates potentially lower risk in terms of short-term price fluctuations for GLAXF.

GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLAXF stands at 75.97B. In comparison, CSPCY has a market cap of 8.38B. Regarding current trading prices, GLAXF is priced at $18.75, while CSPCY trades at $2.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLAXF currently has a P/E ratio of 18.56, whereas CSPCY's P/E ratio is 14.58. In terms of profitability, GLAXF's ROE is +0.22%, compared to CSPCY's ROE of +0.18%. Regarding short-term risk, GLAXF is more volatile compared to CSPCY. This indicates potentially higher risk in terms of short-term price fluctuations for GLAXF.

GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLAXF stands at 75.97B. In comparison, HAWPY has a market cap of 7.96B. Regarding current trading prices, GLAXF is priced at $18.75, while HAWPY trades at $35.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLAXF currently has a P/E ratio of 18.56, whereas HAWPY's P/E ratio is 17.89. In terms of profitability, GLAXF's ROE is +0.22%, compared to HAWPY's ROE of +0.06%. Regarding short-term risk, GLAXF is less volatile compared to HAWPY. This indicates potentially lower risk in terms of short-term price fluctuations for GLAXF.

GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLAXF stands at 75.97B. In comparison, KYKOF has a market cap of 7.72B. Regarding current trading prices, GLAXF is priced at $18.75, while KYKOF trades at $14.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLAXF currently has a P/E ratio of 18.56, whereas KYKOF's P/E ratio is 22.01. In terms of profitability, GLAXF's ROE is +0.22%, compared to KYKOF's ROE of +0.08%. Regarding short-term risk, GLAXF is less volatile compared to KYKOF. This indicates potentially lower risk in terms of short-term price fluctuations for GLAXF.

GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLAXF stands at 75.97B. In comparison, CHJTF has a market cap of 7.36B. Regarding current trading prices, GLAXF is priced at $18.75, while CHJTF trades at $0.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLAXF currently has a P/E ratio of 18.56, whereas CHJTF's P/E ratio is 12.80. In terms of profitability, GLAXF's ROE is +0.22%, compared to CHJTF's ROE of +0.18%. Regarding short-term risk, GLAXF is less volatile compared to CHJTF. This indicates potentially lower risk in terms of short-term price fluctuations for GLAXF.

GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLAXF stands at 75.97B. In comparison, ORINF has a market cap of 6.84B. Regarding current trading prices, GLAXF is priced at $18.75, while ORINF trades at $48.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLAXF currently has a P/E ratio of 18.56, whereas ORINF's P/E ratio is 19.70. In terms of profitability, GLAXF's ROE is +0.22%, compared to ORINF's ROE of +0.37%. Regarding short-term risk, GLAXF is less volatile compared to ORINF. This indicates potentially lower risk in terms of short-term price fluctuations for GLAXF.

GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLAXF stands at 75.97B. In comparison, OPHLF has a market cap of 5.99B. Regarding current trading prices, GLAXF is priced at $18.75, while OPHLF trades at $12.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLAXF currently has a P/E ratio of 18.56, whereas OPHLF's P/E ratio is 11.59. In terms of profitability, GLAXF's ROE is +0.22%, compared to OPHLF's ROE of +0.10%. Regarding short-term risk, GLAXF is less volatile compared to OPHLF. This indicates potentially lower risk in terms of short-term price fluctuations for GLAXF.

GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLAXF stands at 75.97B. In comparison, GIFOF has a market cap of 5.95B. Regarding current trading prices, GLAXF is priced at $18.75, while GIFOF trades at $8.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLAXF currently has a P/E ratio of 18.56, whereas GIFOF's P/E ratio is 31.73. In terms of profitability, GLAXF's ROE is +0.22%, compared to GIFOF's ROE of +0.03%. Regarding short-term risk, GLAXF is more volatile compared to GIFOF. This indicates potentially higher risk in terms of short-term price fluctuations for GLAXF.

GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLAXF stands at 75.97B. In comparison, GRFS has a market cap of 5.94B. Regarding current trading prices, GLAXF is priced at $18.75, while GRFS trades at $7.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLAXF currently has a P/E ratio of 18.56, whereas GRFS's P/E ratio is 28.15. In terms of profitability, GLAXF's ROE is +0.22%, compared to GRFS's ROE of +0.03%. Regarding short-term risk, GLAXF is less volatile compared to GRFS. This indicates potentially lower risk in terms of short-term price fluctuations for GLAXF.

GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLAXF stands at 75.97B. In comparison, DPHAY has a market cap of 5.58B. Regarding current trading prices, GLAXF is priced at $18.75, while DPHAY trades at $98.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLAXF currently has a P/E ratio of 18.56, whereas DPHAY's P/E ratio is -155.56. In terms of profitability, GLAXF's ROE is +0.22%, compared to DPHAY's ROE of -0.04%. Regarding short-term risk, GLAXF is more volatile compared to DPHAY. This indicates potentially higher risk in terms of short-term price fluctuations for GLAXF.

GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLAXF stands at 75.97B. In comparison, GIFLF has a market cap of 5.25B. Regarding current trading prices, GLAXF is priced at $18.75, while GIFLF trades at $8.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLAXF currently has a P/E ratio of 18.56, whereas GIFLF's P/E ratio is 32.69. In terms of profitability, GLAXF's ROE is +0.22%, compared to GIFLF's ROE of +0.03%. Regarding short-term risk, GLAXF is less volatile compared to GIFLF. This indicates potentially lower risk in terms of short-term price fluctuations for GLAXF.

GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLAXF stands at 75.97B. In comparison, OPHLY has a market cap of 5.11B. Regarding current trading prices, GLAXF is priced at $18.75, while OPHLY trades at $3.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLAXF currently has a P/E ratio of 18.56, whereas OPHLY's P/E ratio is 10.06. In terms of profitability, GLAXF's ROE is +0.22%, compared to OPHLY's ROE of +0.10%. Regarding short-term risk, GLAXF is less volatile compared to OPHLY. This indicates potentially lower risk in terms of short-term price fluctuations for GLAXF.

GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLAXF stands at 75.97B. In comparison, SNPHY has a market cap of 3.47B. Regarding current trading prices, GLAXF is priced at $18.75, while SNPHY trades at $10.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLAXF currently has a P/E ratio of 18.56, whereas SNPHY's P/E ratio is 18.46. In terms of profitability, GLAXF's ROE is +0.22%, compared to SNPHY's ROE of +0.06%. Regarding short-term risk, GLAXF is more volatile compared to SNPHY. This indicates potentially higher risk in terms of short-term price fluctuations for GLAXF.

GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLAXF stands at 75.97B. In comparison, PTKFF has a market cap of 3.43B. Regarding current trading prices, GLAXF is priced at $18.75, while PTKFF trades at $0.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLAXF currently has a P/E ratio of 18.56, whereas PTKFF's P/E ratio is N/A. In terms of profitability, GLAXF's ROE is +0.22%, compared to PTKFF's ROE of +0.15%. Regarding short-term risk, GLAXF is more volatile compared to PTKFF. This indicates potentially higher risk in terms of short-term price fluctuations for GLAXF.

GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLAXF stands at 75.97B. In comparison, SNPHF has a market cap of 3.30B. Regarding current trading prices, GLAXF is priced at $18.75, while SNPHF trades at $9.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLAXF currently has a P/E ratio of 18.56, whereas SNPHF's P/E ratio is 17.82. In terms of profitability, GLAXF's ROE is +0.22%, compared to SNPHF's ROE of +0.06%. Regarding short-term risk, GLAXF is less volatile compared to SNPHF. This indicates potentially lower risk in terms of short-term price fluctuations for GLAXF.

GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLAXF stands at 75.97B. In comparison, VRBCF has a market cap of 2.71B. Regarding current trading prices, GLAXF is priced at $18.75, while VRBCF trades at $324.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLAXF currently has a P/E ratio of 18.56, whereas VRBCF's P/E ratio is 16.51. In terms of profitability, GLAXF's ROE is +0.22%, compared to VRBCF's ROE of +0.14%. Regarding short-term risk, GLAXF is more volatile compared to VRBCF. This indicates potentially higher risk in terms of short-term price fluctuations for GLAXF.

GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLAXF stands at 75.97B. In comparison, OGN has a market cap of 2.28B. Regarding current trading prices, GLAXF is priced at $18.75, while OGN trades at $8.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLAXF currently has a P/E ratio of 18.56, whereas OGN's P/E ratio is 3.04. In terms of profitability, GLAXF's ROE is +0.22%, compared to OGN's ROE of +1.82%. Regarding short-term risk, GLAXF is less volatile compared to OGN. This indicates potentially lower risk in terms of short-term price fluctuations for GLAXF.

GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLAXF stands at 75.97B. In comparison, HAWPF has a market cap of 2.21B. Regarding current trading prices, GLAXF is priced at $18.75, while HAWPF trades at $10.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLAXF currently has a P/E ratio of 18.56, whereas HAWPF's P/E ratio is 12.66. In terms of profitability, GLAXF's ROE is +0.22%, compared to HAWPF's ROE of +0.06%. Regarding short-term risk, GLAXF is more volatile compared to HAWPF. This indicates potentially higher risk in terms of short-term price fluctuations for GLAXF.

GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLAXF stands at 75.97B. In comparison, LYPHF has a market cap of 1.01B. Regarding current trading prices, GLAXF is priced at $18.75, while LYPHF trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLAXF currently has a P/E ratio of 18.56, whereas LYPHF's P/E ratio is 13.40. In terms of profitability, GLAXF's ROE is +0.22%, compared to LYPHF's ROE of +0.06%. Regarding short-term risk, GLAXF is less volatile compared to LYPHF. This indicates potentially lower risk in terms of short-term price fluctuations for GLAXF.

GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLAXF stands at 75.97B. In comparison, CMOPF has a market cap of 880.83M. Regarding current trading prices, GLAXF is priced at $18.75, while CMOPF trades at $55.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLAXF currently has a P/E ratio of 18.56, whereas CMOPF's P/E ratio is 5.98. In terms of profitability, GLAXF's ROE is +0.22%, compared to CMOPF's ROE of +0.14%. Regarding short-term risk, GLAXF is more volatile compared to CMOPF. This indicates potentially higher risk in terms of short-term price fluctuations for GLAXF.

GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLAXF stands at 75.97B. In comparison, TGRNF has a market cap of 790.76M. Regarding current trading prices, GLAXF is priced at $18.75, while TGRNF trades at $0.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLAXF currently has a P/E ratio of 18.56, whereas TGRNF's P/E ratio is 10.29. In terms of profitability, GLAXF's ROE is +0.22%, compared to TGRNF's ROE of +0.09%. Regarding short-term risk, GLAXF is less volatile compared to TGRNF. This indicates potentially lower risk in terms of short-term price fluctuations for GLAXF.

GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLAXF stands at 75.97B. In comparison, JCRRF has a market cap of 556.74M. Regarding current trading prices, GLAXF is priced at $18.75, while JCRRF trades at $4.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLAXF currently has a P/E ratio of 18.56, whereas JCRRF's P/E ratio is -228.50. In terms of profitability, GLAXF's ROE is +0.22%, compared to JCRRF's ROE of -0.01%. Regarding short-term risk, GLAXF is less volatile compared to JCRRF. This indicates potentially lower risk in terms of short-term price fluctuations for GLAXF.

GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLAXF stands at 75.97B. In comparison, MAYNF has a market cap of 340.01M. Regarding current trading prices, GLAXF is priced at $18.75, while MAYNF trades at $4.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLAXF currently has a P/E ratio of 18.56, whereas MAYNF's P/E ratio is -4.18. In terms of profitability, GLAXF's ROE is +0.22%, compared to MAYNF's ROE of -0.35%. Regarding short-term risk, GLAXF is more volatile compared to MAYNF. This indicates potentially higher risk in terms of short-term price fluctuations for GLAXF.

GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLAXF stands at 75.97B. In comparison, CTOR has a market cap of 60.60M. Regarding current trading prices, GLAXF is priced at $18.75, while CTOR trades at $0.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLAXF currently has a P/E ratio of 18.56, whereas CTOR's P/E ratio is -2.57. In terms of profitability, GLAXF's ROE is +0.22%, compared to CTOR's ROE of -0.15%. Regarding short-term risk, GLAXF is less volatile compared to CTOR. This indicates potentially lower risk in terms of short-term price fluctuations for GLAXF.

GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLAXF stands at 75.97B. In comparison, SCLXW has a market cap of 47.74M. Regarding current trading prices, GLAXF is priced at $18.75, while SCLXW trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLAXF currently has a P/E ratio of 18.56, whereas SCLXW's P/E ratio is N/A. In terms of profitability, GLAXF's ROE is +0.22%, compared to SCLXW's ROE of +0.36%. Regarding short-term risk, GLAXF is less volatile compared to SCLXW. This indicates potentially lower risk in terms of short-term price fluctuations for GLAXF.

GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLAXF stands at 75.97B. In comparison, SCLX has a market cap of 32.01M. Regarding current trading prices, GLAXF is priced at $18.75, while SCLX trades at $4.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLAXF currently has a P/E ratio of 18.56, whereas SCLX's P/E ratio is -0.22. In terms of profitability, GLAXF's ROE is +0.22%, compared to SCLX's ROE of +0.36%. Regarding short-term risk, GLAXF is less volatile compared to SCLX. This indicates potentially lower risk in terms of short-term price fluctuations for GLAXF.

GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLAXF stands at 75.97B. In comparison, PTKFY has a market cap of 21.50M. Regarding current trading prices, GLAXF is priced at $18.75, while PTKFY trades at $18.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLAXF currently has a P/E ratio of 18.56, whereas PTKFY's P/E ratio is 21.41. In terms of profitability, GLAXF's ROE is +0.22%, compared to PTKFY's ROE of +0.15%. Regarding short-term risk, GLAXF is more volatile compared to PTKFY. This indicates potentially higher risk in terms of short-term price fluctuations for GLAXF.

GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLAXF stands at 75.97B. In comparison, MIRA has a market cap of 19.50M. Regarding current trading prices, GLAXF is priced at $18.75, while MIRA trades at $1.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLAXF currently has a P/E ratio of 18.56, whereas MIRA's P/E ratio is -2.27. In terms of profitability, GLAXF's ROE is +0.22%, compared to MIRA's ROE of -2.82%. Regarding short-term risk, GLAXF is less volatile compared to MIRA. This indicates potentially lower risk in terms of short-term price fluctuations for GLAXF.

GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLAXF stands at 75.97B. In comparison, SRXH has a market cap of 10.11M. Regarding current trading prices, GLAXF is priced at $18.75, while SRXH trades at $0.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLAXF currently has a P/E ratio of 18.56, whereas SRXH's P/E ratio is N/A. In terms of profitability, GLAXF's ROE is +0.22%, compared to SRXH's ROE of N/A. Regarding short-term risk, GLAXF is less volatile compared to SRXH. This indicates potentially lower risk in terms of short-term price fluctuations for GLAXF.

GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLAXF stands at 75.97B. In comparison, PSYGF has a market cap of 1.08M. Regarding current trading prices, GLAXF is priced at $18.75, while PSYGF trades at $0.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLAXF currently has a P/E ratio of 18.56, whereas PSYGF's P/E ratio is -0.02. In terms of profitability, GLAXF's ROE is +0.22%, compared to PSYGF's ROE of +2.78%. Regarding short-term risk, GLAXF is less volatile compared to PSYGF. This indicates potentially lower risk in terms of short-term price fluctuations for GLAXF.

GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLAXF stands at 75.97B. In comparison, CRXTQ has a market cap of 72829.00. Regarding current trading prices, GLAXF is priced at $18.75, while CRXTQ trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLAXF currently has a P/E ratio of 18.56, whereas CRXTQ's P/E ratio is -0.00. In terms of profitability, GLAXF's ROE is +0.22%, compared to CRXTQ's ROE of +0.33%. Regarding short-term risk, GLAXF is more volatile compared to CRXTQ. This indicates potentially higher risk in terms of short-term price fluctuations for GLAXF.

GLAXF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GLAXF stands at 75.97B. In comparison, CRXT comparison data is unavailable. Regarding current trading prices, GLAXF is priced at $18.75, while CRXT trades at $0.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GLAXF currently has a P/E ratio of 18.56, whereas CRXT's P/E ratio is -0.02. In terms of profitability, GLAXF's ROE is +0.22%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, GLAXF is less volatile compared to CRXT. This indicates potentially lower risk in terms of short-term price fluctuations for GLAXF.